Hot or Cold

CBRS stock sentiment todayCerebras Systems Inc

Sentiment verdict

Gossip first, financials second — NEUTRAL at 65% confidence.

Last updated · cached analysis, refreshes periodically

NASDAQ

CBRS

Cerebras Systems Inc
109.18 USD▲ 1.56%vs. session open
After hours · market closedQuote as of Nov 1, 08:21 AM UTC
NEUTRAL65% confidenceSign in to save

A high-beta AI pure-play caught between massive architectural potential and concentrated revenue risks amplified by recent short-seller scrutiny.

Analyzed Oct 31, 2026, 08:36 AM UTC·Quote: CNBC / Yahoo Finance·News: Google News·Targets: StockAnalysis.com·AI: Lovable AI (google/gemini-3-flash-preview)
Tone“CBRS is NEUTRAL — A high-beta AI pure-play caught between massive architectural potential and concentrated revenue risks amplified by recent short-seller scrutiny. 6-month call: USD148.40 (+35.9%).”
6-month price prediction
USD148.40▲ 35.9%by May 2027
40% model confidence
Bear USD59.36Now USD109.18Bull USD237.43
Crowd call · 6 months
No predictions yet

Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.

Make your call as a guest

You'll show up on boards and The Floor under this name. Add an email later to keep your history.

No account needed. You can add an email later to keep your calls.

Already have an account? Sign in

🔒 Full prediction model breakdown

See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.

Sign in to go Pro →

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for CBRS. Not financial advice.

02·a

Price · last 12 months

108.37 – 311.07 USD
Growth
1W
-1.5%
1M
-38.5%
3M
-50.4%
6M
-64.9%
YTD
-64.9%
1Y
-64.9%
01

Gossip

mixed

The narrative is a tug-of-war between 'Nvidia-killer' enthusiasts and skeptics. Recent volatility is driven by a short report from Culper Research questioning accounting and customer concentration, partially offset by a major partnership with Oracle Cloud.

  • ·Short report impact from Culper Research
  • ·Oracle Cloud infrastructure partnership
  • ·Post-IPO volatility and lock-up expiration fears
  • ·G42 revenue concentration concerns
02

Financial

average

Cerebras shows explosive revenue growth (tripling YoY) but remains heavily reliant on a single customer (G42) for over 80% of revenue. Margins are improving due to the Wafer-Scale Engine (WSE-3) efficiency, though R&D spend keeps them in a net loss position.

  • ·Revenue Growth: >200% YoY
  • ·Gross Margin: ~40-45% (lower than NVDA)
  • ·Customer Concentration: >80% (G42 Group)
  • ·Cash Runway: Sufficient post-IPO but high burn
02b

Conviction

Hollow

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

20conviction score / 100

Hollow — insiders are stepping back and the register is short-horizon.

  • ·Insiders sold a net $10.5M on the open market in the last 120 days.
Insider buys (120d)
0
Net insider flow
-$10.5M
Patient capital
8%
🔒 Who bought, and who's holding

Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.

Unlock with Pro →

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

03

Risks

watch
  • ·Extreme revenue concentration in a single Middle Eastern entity (G42)
  • ·Regulatory risk regarding AI chip export controls to the UAE
  • ·Execution risk of the 'Wafer-Scale' manufacturing process at scale
  • ·Intense competition from hyperscaler in-house silicon (TPU, Trainium)
05

Analyst price target

HOT
287.30 USD▲ 163.1% vs current

Consensus average of 10 analysts · median 300.00

Low 209.00High 330.00

Source: StockAnalysis.com · updated 2026-10-05

AI-generated analysis for informational purposes only. Not financial advice.